Research Article
Prognostic Nomogram for Gastrointestinal Stromal Tumors after Surgery Based on the SEER Database
Table 1
Characteristics of patients with gastrointestinal stromal tumors in the training and validation groups.
| | Characteristic | Whole population | Training cohort | Validation cohort |
| | Total patients | 4157 | 2910 | 1247 | | Age at diagnosis (years) | 63 (53, 71) | 63 (53, 71) | 63 (53, 72) | | Sex | | | | | Male | 2017 (48.5) | 1420 (48.8) | 597 (47.9) | | Female | 2140 (51.5) | 1490 (51.2) | 650 (52.1) | | Race | | | | | White | 2799 (67.3) | 1950 (67.0) | 849 (68.1) | | Black | 740 (17.8) | 521 (17.9) | 219 (17.6) | | Other | 618 (14.9) | 439 (15.1) | 179 (14.4) | | Tumor location | | | | | Stomach | 2625 (63.1) | 1840 (63.2) | 785 (63.0) | | Small intestine | 1207 (29.0) | 845 (29.0) | 362 (29.0) | | Colorectum | 132 (3.2) | 93 (3.2) | 39 (3.1) | | Other | 193 (4.6) | 132 (4.5) | 61 (4.9) | | Tumor grade | | | | | Well/moderately differentiated | 1640 (39.5) | 1143 (39.3) | 497 (39.9) | | Poorly differentiated/undifferentiated | 460 (11.1) | 329 (11.3) | 131 (10.5) | | Unknown | 2057 (49.5) | 1438 (49.4) | 619 (49.6) | | Tumor size | | | | | ≤2 cm | 526 (12.7) | 372 (12.8) | 154 (12.3) | | 2-5 cm | 1360 (32.7) | 939 (32.3) | 421 (33.8) | | 5-10 cm | 1300 (31.3) | 908 (31.2) | 392 (31.4) | | >10 cm | 971 (23.4) | 691 (23.7) | 280 (22.5) | | AJCC stage | | | | | I | 1867 (44.9) | 1291 (44.4) | 576 (46.2) | | II | 661 (15.9) | 470 (16.2) | 191 (15.3) | | III | 701 (16.9) | 510 (17.5) | 191 (15.3) | | IV | 450 (10.8) | 299 (10.3) | 151 (12.1) | | Unknown | 478 (11.5) | 340 (11.7) | 138 (11.1) | | Mitotic rate | | | | | ≤5/5 mm2 HPF | 2256 (54.3) | 1573 (54.1) | 683 (54.8) | | >5/5 mm2 HPF | 932 (22.4) | 648 (22.3) | 284 (22.8) | | Unknown | 969 (23.3) | 689 (23.7) | 280 (22.5) | | Surgery | | | | | Local excision | 516 (12.4) | 363 (12.5) | 153 (12.3) | | Radical excision | 3594 (86.5) | 2515 (86.4) | 1079 (86.5) | | Other | 47 (1.1) | 32 (1.1) | 15 (1.2) | | RNE | | | | | 0 | 2911 (70.0) | 2050 (70.4) | 861 (69.0) | | 1-4 | 599 (14.4) | 414 (14.2) | 185 (14.8) | | >4 | 647 (15.6) | 446 (15.3) | 201 (16.1) | | Chemotherapy | | | | | No/unknown | 2323 (55.9) | 1633 (56.1) | 690 (55.3) | | Yes | 1834 (44.1) | 1277 (43.9) | 557 (44.7) | | Survival (months) | 45 (22, 73) | 45 (22, 73) | 45 (21, 72) |
|
|
AJCC stage: American Joint Committee on Cancer stage; HPF: high-power microscopic fields; RNE: regional nodes examined.
|
